Author

Woori Ko

Institution: Celltrion (South Korea)

Observed institution: Celltrion (South Korea)

OpenAlex ID: A5113051998

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

2023 · Kim A. Papp, Mark G. Lebwohl, et al. · BioDrugs · 33

Efficacy and Safety of CT‐P43, a Candidate Ustekinumab Biosimilar, in Moderate‐to‐Severe Plaque Psoriasis: 52‐Week Results From a Randomised, Active‐Controlled, Double‐Blind, Phase III Study

2026 · Kim A. Papp, Janusz Jaworski, et al. · Dermatologic Therapy

Effect of NovoNorm on Efficacy,Tolerability and Quality of Life in Patients with Type 2 Diabetes Mellitus

2003 · Tsai-Sung Tai, Hsiu-Chu Lin, et al. · Taipei Medical University Repository

Works count: 3

Citation count: 33

H-index: 1

I10-index: 1